99. J Gynecol Obstet Hum Reprod. 2018 Jun;47(6):261-264. doi:10.1016/j.jogoh.2018.03.002. Epub 2018 Mar 3.Ovarian suppression failure during GnRH agonist treatment: A report of threebreast cancer patients.de Ciantis M(1), Faure C(2), Heudel PE(3), Tredan O(3), Rousset-Jablonski C(4).Author information: (1)Université Claude Bernard, Domaine Rockefeller, 8 avenue Rockefeller, 69373Lyon Cedex 8, France.(2)Département de Chirurgie, Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon,France.(3)Département de Cancérologie Médicale, Centre Léon-Bérard, 28 rue Laënnec,69008 Lyon, France.(4)Département de Chirurgie, Centre Léon Bérard, 28 rue Laënnec, 69008 Lyon,France; Service de Gynécologie, Centre Hospitalier Lyon Sud, 165 chemin du grand Revoyet, 69130 Pierre-Bénite, France. Electronic address:christine.rousset-jablonski@lyon.unicancer.fr.In premenopausal women treated for breast cancer, endocrine therapy combining an aromatase inhibitor (AI) and a gonadotropin-releasing hormone (GnRH) agonist (GA)for ovarian suppression may be indicated in high-risk or in metastatic cancer.AIs are effective in premenopausal women only when ovarian estrogen production issuppressed, a state achievable through the use of GAs. However, a completesuppression sometimes proves elusive. We report here three cases of ovariansuppression failure in premenopausal breast cancer patients who received adjuvantAI+GA. Frequency of GA administration, BMI, and young age could affectgonadotropin suppression and may be implied in these failures. Clinicalmonitoring of these patients is advisable, and hormone assays and pelvicultrasound should be performed in case of symptoms of estrogen activity.Copyright © 2018 Elsevier Masson SAS. All rights reserved.DOI: 10.1016/j.jogoh.2018.03.002 PMID: 29510273 